The results of the present study revealed that all NAFLD groups except the combination therapy group (NAFLD+LGG+Exe) had a significant decrease in α-SMA compared to the healthy control group. The gene discussed is ACTA1; the disease is metabolic dysfunction-associated steatotic liver disease.